BCLI - ブレインスト―ム・セル・セラピュ―ティクス (Brainstorm Cell Therapeutics Inc.) ブレインスト―ム・セル・セラピュ―ティクス

 BCLIのチャート


 BCLIの企業情報

symbol BCLI
会社名 Brainstorm Cell Therapeutics Inc (ブレインスト―ム・セル・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS also known as Lou Gehrig's disease) Multiple Sclerosis (MS) and Parkinson's disease (PD) among others. Its subsidiary Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary) holds rights to commercialize the technology NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.   ブレインスト―ム・セル・セラピュ―ティクスは、米国のバイオテクノロジ―会社。筋萎縮性側索硬化症(ル―・ゲ―リック病としても知られている)、多発性硬化症、およびパ―キンソン病などの神経変性疾患を衰弱させるための成体幹細胞治療を開発する。「NurOwn」は、同社独自のプロセスで、神経変性疾患を治療するために設計されている。   Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
本社所在地 1325 Avenue of Americas 28th Floor New York NY 10019 USA
代表者氏名 Irit Arbel Irit Arbel
代表者役職名 Independent Chairman of the Board
電話番号 +1 201-488-0460
設立年月日 36770
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 24人
url www.brainstorm-cell.com
nasdaq_url https://www.nasdaq.com/symbol/bcli
adr_tso
EBITDA EBITDA(百万ドル) -7.44100
終値(lastsale) 3.62
時価総額(marketcap) 74823691.36
時価総額 時価総額(百万ドル) 75.44378
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 58.00478
当期純利益 当期純利益(百万ドル) -7.51600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Brainstorm Cell Therapeutics Inc revenues was not reported. Net loss increased 91% to $5.4M. Higher net loss reflects General and administrative - Balancing v increase of 93% to $2.6M (expense) Research and development - Balancing val increase of 85% to $2.4M (expense) Stock-based Compensation in SGA increase from $108K to $315K (expense).

 BCLIのテクニカル分析


 BCLIのニュース

   Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility  2020/10/26 10:00:00 PR Newswire
PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that…
   Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Rating Lowered by BidaskClub  2020/10/25 08:06:46 Zolmax News
Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday, BidAskClub reports. Separately, Maxim Group upped their price objective on shares of Brainstorm Cell Therapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a research report […]
   Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Up 7.2%  2020/10/22 18:52:47 US Banking News
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) rose 7.2% on Thursday . The company traded as high as $10.89 and last traded at $10.19. Approximately 1,630,678 shares traded hands during trading, an increase of 150% from the average daily volume of 652,189 shares. The stock had previously closed at $9.51. BCLI has been the subject […]
   Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®  2020/10/22 13:00:00 GlobeNewswire
SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies,…
   Stock Traders Buy Large Volume of Call Options on Brainstorm Cell Therapeutics (NASDAQ:BCLI)  2020/10/21 08:58:48 Dakota Financial News
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of some unusual options trading activity on Monday. Stock traders acquired 9,584 call options on the company. This represents an increase of approximately 500% compared to the average volume of 1,597 call options. Shares of BCLI opened at $10.15 on Wednesday. The company has a market capitalization […]
   Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility  2020/10/26 10:00:00 PR Newswire
PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that…
   Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Rating Lowered by BidaskClub  2020/10/25 08:06:46 Zolmax News
Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday, BidAskClub reports. Separately, Maxim Group upped their price objective on shares of Brainstorm Cell Therapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a research report […]
   Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Up 7.2%  2020/10/22 18:52:47 US Banking News
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) rose 7.2% on Thursday . The company traded as high as $10.89 and last traded at $10.19. Approximately 1,630,678 shares traded hands during trading, an increase of 150% from the average daily volume of 652,189 shares. The stock had previously closed at $9.51. BCLI has been the subject […]
   Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®  2020/10/22 13:00:00 GlobeNewswire
SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies,…
   Stock Traders Buy Large Volume of Call Options on Brainstorm Cell Therapeutics (NASDAQ:BCLI)  2020/10/21 08:58:48 Dakota Financial News
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of some unusual options trading activity on Monday. Stock traders acquired 9,584 call options on the company. This represents an increase of approximately 500% compared to the average volume of 1,597 call options. Shares of BCLI opened at $10.15 on Wednesday. The company has a market capitalization […]
   Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility  2020/10/26 10:00:00 PR Newswire
PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that…
   Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Rating Lowered by BidaskClub  2020/10/25 08:06:46 Zolmax News
Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday, BidAskClub reports. Separately, Maxim Group upped their price objective on shares of Brainstorm Cell Therapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a research report […]
   Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Up 7.2%  2020/10/22 18:52:47 US Banking News
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) rose 7.2% on Thursday . The company traded as high as $10.89 and last traded at $10.19. Approximately 1,630,678 shares traded hands during trading, an increase of 150% from the average daily volume of 652,189 shares. The stock had previously closed at $9.51. BCLI has been the subject […]
   Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®  2020/10/22 13:00:00 GlobeNewswire
SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies,…
   Stock Traders Buy Large Volume of Call Options on Brainstorm Cell Therapeutics (NASDAQ:BCLI)  2020/10/21 08:58:48 Dakota Financial News
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of some unusual options trading activity on Monday. Stock traders acquired 9,584 call options on the company. This represents an increase of approximately 500% compared to the average volume of 1,597 call options. Shares of BCLI opened at $10.15 on Wednesday. The company has a market capitalization […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ブレインスト―ム・セル・セラピュ―ティクス BCLI Brainstorm Cell Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)